Erlotinib (Management of Resistance)
The development of second- and third-generation EGFR inhibitors, such as afatinib and Osimertinib, aims to overcome resistance to first-generation TKIs like erlotinib. These newer agents can target common resistance mutations and offer additional treatment options for patients.